StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Xeris Biopharma's profit margin for the twelve months ending Jun 30, 2026 was -5.1%. For fiscal 2025 it was 0.2%, against -27.0% the year before. The highest annual figure on record is 0.2% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20250.2%+27.2
FY2024Dec 31, 2024-27.0%+11.0
FY2023Dec 31, 2023-38.0%+47.9
FY2022Dec 31, 2022-85.9%+161.6
FY2021Dec 31, 2021-247.5%+198.5
FY2020Dec 31, 2020-446.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-33.8%−31.1
Q1 FY2026Mar 31, 20262.7%+18.0
Q4 FY2025Dec 31, 202512.9%+21.4
Q3 FY2025Sep 30, 20250.8%+29.8
Q2 FY2025Jun 30, 2025-2.7%+28.5
Q1 FY2025Mar 31, 2025-15.3%+31.4
Q4 FY2024Dec 31, 2024-8.5%+21.7
Q3 FY2024Sep 30, 2024-29.0%−3.8
Q2 FY2024Jun 30, 2024-31.2%+21.0
Q1 FY2024Mar 31, 2024-46.7%+4.0
Q4 FY2023Dec 31, 2023-30.2%+8.8
Q3 FY2023Sep 30, 2023-25.2%+48.2
Q2 FY2023Jun 30, 2023-52.2%+51.3
Q1 FY2023Mar 31, 2023-50.7%+102.0
Q4 FY2022Dec 31, 2022-39.0%+198.0
Q3 FY2022Sep 30, 2022-73.4%+161.7
Q2 FY2022Jun 30, 2022-103.5%+205.5
Q1 FY2022Mar 31, 2022-152.7%+71.9
Q4 FY2021Dec 31, 2021-237.0%+59.6
Q3 FY2021Sep 30, 2021-235.2%−65.0
Q2 FY2021Jun 30, 2021-308.9%–
Q1 FY2021Mar 31, 2021-224.7%–
Q4 FY2020Dec 31, 2020-296.6%–
Q3 FY2020Sep 30, 2020-170.1%–

More Xeris Biopharma figures

See a number that looks wrong?